Summary Recombinant human erythropoietin (rHuEPO) has been advocated for the treatment of anaemia in patients submitted to cancer chemotherapy. We used decision analysis to compare the cost-effectiveness of rHuEPO supplemented with red blood cell (RBC) transfusions with conventional treatment with RBC transfusions alone. At Anaemia is a frequent complication in patients with cancer receiving cytotoxic chemotherapy. It impairs patients' physical capabilities and subjective sense of well-being, diminishing their quality of life. In controlled randomized studies, rHuEPO was associated with increased haemoglobin level, decreased transfusion requirements and improved quality of life (Abels, 1993; Case et al, 1993; Finelli et al, 1993; Cascinu et al, 1994; Henry and Abels, 1994; Cazzola et al, 1995; De Campos et al, 1995; Garton et al, 1995; Oesterborg et al, 1996; ten Bokkel-Huinink, 1996; Wurnig et al, 1996; Del Mastro et al, 1997) . As the same results were obtained in a community oncology practice setting (Glaspy et al, 1997), recommendations for rHuEPO use and a treatment algorithm for its optimization were outlined (Glaspy et al, 1997).
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In contrast, because of increasing financial constraints throughout health care systems, the amount of money allotted for a new treatment has to be considered in relation to the magnitude of the benefit offered with respect to traditional therapy. As a consequence, cost-effectiveness analysis belongs to the development process aimed at establishing policy for drug use. The purpose of this work is to provide a cost-effectiveness analysis of rHuEPO in the chemotherapy-induced anaemia of cancer.
METHODS

Base case
As the best strategy for administering rHuEPO to patients undergoing cancer chemotherapy has not yet been determined, at baseline we modelled the most resource-saving treatment strategy, i.e. the use of the drug for secondary prophylaxis, reserved for patients who had developed severe anaemia as a consequence of chemotherapy. The case upon which this analysis is based was derived from the results of a community-based US multicentre oncology study (Glaspy et al, 1997) . As such, a hypothetical typical patient fulfilling the criteria for therapy receives treatment at a mean age of 65 years, does not carry any other cause for anaemia except cancer chemotherapy, always has an expected survival of more than 6 months and is treated with rHuEPO when haemoglobin falls below 10.7 g dl-'. To better reflect the health care system perspective, we assumed that both rHuEPO and RBC transfusions were administered in the hospital. We outlined our model on the basis of a 4-month course of rHuEPO with doses of 150 units kg-' three times per week, i.e. according to the protocol providing treatment guidance for patients in the community setting.
The decision model The model (developed using DATA software for Windows, Tree Age Software, Boston, MA, USA) evaluated two clinical management strategies: experimental prophylactic use of rHuEPO supplemented with RBC transfusions and conventional treatment with RBC 781 transfusions alone (Figure 1 ). In both strategies, patients were subdivided according to their chance of being transfused during the following 4 months of chemotherapy. In the strategy of employing rHuEPO, the model depicted the chance of response, i.e. of increasing haemoglobin level by more than 2 g dl-I with respect to the baseline value. This outcome was considered to change the quality of life of these patients. Even though the general policy of oncological institutions is not to administer RBC transfusions unless the haemoglobin level drops below 8 g dl' (Glaspy et al, 1997) , in the strategy of transfusions alone we modelled a response similar to that in the rHuEPO arm. In the baseline analysis, transfusions were considered to be palliative and not to increase haemoglobin levels or change the patients' quality of life. A hypothetical transfusion pattern that approximates to haemoglobin response obtained with a successful rHuEPO therapy was outlined in the scenario analysis.
With both strategies, patients receiving transfusions were at risk for acute or long-standing adverse effects. The risk was that of a single RBC unit multiplied by the number of units transfused. Transfusion reactions contributed only their costs, whereas bloodborne infections due to hepatitis C virus (HCV) and human immunodeficiency virus (HIV) carried mortality, morbidity and costs. Their outcomes were explicitly outlined in the model. Following HCV infection, a proportion of patients die of acute hepatitis. Later, there is a low sequential progression from acute viral infection to chronic hepatitis, cirrhosis and, eventually, hepatocellular carcinoma. Hepatitis B virus (HBV), cytomegalovirus (CMV) or human T-cell lymphotrophic virus (HTLV) infections were cumulatively considered for their chance to develop posttransfusional adverse events, and were considered to contribute only to costs. As a matter of fact, although the acquisition of hepatitis B virus through transfusions is reported to be from I in 3300 (Donahue et al, 1992) to 1 in 63 000 (Schreiber et al, 1996) , the probability of developing acute or chronic hepatitis B is nearly null (Blajchman et al, 1995) ; donor antibody screening and/or the use of white cell reduction filters have virtually eliminated cytomegalovirus infections (Dodd, 1992) , and human T-cell lymphotrophic virus strain I or 2 is reported to infect I in 641 000 without mortality (Schreiber et al, 1996) . Each decision pathway ends with a terminal node related to its utility. We framed utility on two different dimensions: the cost of the health care resources used and the qualityadjusted life expectancy for the various health states.
We defined the incremental cost-effectiveness of secondary prophylaxis with rHuEPO as the net change in the amount of health care resources required to administer the drug, as opposed to not administering it, divided by the net change in the amount of health benefits resulting from this substitution.
To 
Scenario analysis
Scenario analysis allows one to examine how the optimality of a strategy will be affected by conceivable changes in structural assumptions. In a scenario analysis, we considered cisplatincontaining chemotherapy-treated patients, i.e. the cytotoxic therapy with the highest probability of severe anaemia, but also the one with the best response rate to rHuEPO. A hypothetical scenario was devised to simulate the transfusion pattern that would be necessary to approximate to the maintained haemoglobin response seen with rHuEPO. Patients developing anaemia during chemotherapy were assumed to receive transfusions to increase the baseline haemoglobin value by more than 2 g dl-1.
Assumptions
In an economic analysis of rHuEPO use in patients with the anaemia of cancer, some assumptions can be made.
1. Side-effects from rHuEPO therapy like hypertension and thrombosis, which are not rare in end-stage renal disease but are rare in cancer patients, need not be considered. 2. The cost of both iron replacement during rHuEPO and of iron chelation during transfusion therapy is usually small compared with overall treatment cost in renal anaemia (Leese et al, 1992) , and even smaller in the anaemia of cancer because of the shorter treatment time. 3. The immunomodulating effects of allogeneic transfusions need not be considered, because current evidence for these effects comes primarily from retrospective studies. 4. Loss of productivity, which is an indirect cost of transfusion administration, is negligible because rHuEPO therapy is employed only during severe disease phases when the patient is out of work. 5. The possible long-term effects of transfusional therapy caused by blood-borne infections can be weighted against the limited duration of life expectancy for cancer. In baseline analysis, we assumed a mean life expectancy of 5 years for these patients. This assumption was chosen operatively and its impact on the cost-effectiveness results was examined by sensitivity analysis.
Data on effectiveness
The probabilities of the model outcomes were estimated by sources identified through repeated computer searches of the Medline medical literature and from the reference list of relevant papers. When assumptions or estimates were equivocal, we assigned values that tended to bias our results in favour of rHuEPO.
Response to rHuEPO treatment Baseline data on the effectiveness of secondary prophylaxis for anaemia with rHuEPO in patients with any form of cancer were derived from the largest study on community-based oncologists (Glaspy et al, 1997) and are reported in Table 1 . These values were within the range of the data from randomized clinical trials on secondary prophylaxis (Abels, 1993; Cascinu et al, 1994; Wurnig et al, 1996) . The best estimates from randomized clinical trials were: for probability of transfusion, 56% in placebo and 20% in rHuEPO-treated patients; and for transfusion load, 1.8 units per month in placebo and 0.30 in treated patients. These values were used in the sensitivity analysis. For cisplatin-treated patients, the estimated average rHuEPO response rate was derived from a prospective, randomized, .
In the scenario of transfusion policy aimed at approximating to the haemoglobin response seen with rHuEPO, the average transfusion requirement was set at 2 units per month, as reported in patients with renal anaemia to maintain a sustained haemoglobin level (Scheingold et al, 1992 ).
Risk of blood-borne infections
The overall per unit rate of post-transfusion diseases is reported in Table 2 . The 0.4 per 1000 incidence of HCV hepatitis was derived from a study on patients receiving allogeneic blood after HCV screening in Canada (Blajchman et al, 1995) , and was quite similar to the 3 per 10 000 transfused units reported in patients receiving blood between 1985 and 1991 in the United States (Donahue et al, 1992) . The post-hepatitis outcomes were derived from a prospective, population-based study (Tong et al, 1995) . The annual incidence rates of chronic hepatitis, liver cirrhosis, liver carcinoma and hepatitis-associated deaths were calculated from the total incidence rate and the number of patient-years of follow-up. This was obtained by assuming that in that study all the patients with serious liver disease related to post-transfusion HCV in the reference population had been observed, and that the risk of developing liver diseases had a normal distribution over time. The final results were similar to other data in the literature. The 20% rate of clinical evidence of cirrhosis in patients with HCV infection 16 years after the initial blood transfusion (Koretz et al, 1993) was quite similar to the cumulative rate of 21.1 % we calculated. The results were, however, in disagreement with other studies that reported that very few patients showed complications of chronic infection after an average follow-up of 18 years (Seeff et al, 1992) . The percentage of liver-related mortality (0.59% per year) was higher than the mortality in other long-term, prospective cohort studies (Koretz et al, 1985; Alter et al, 1988 ) that described a mortality of 0.35% per year: however, in these latter studies the follow-up was shorter than in our reference study.
The per unit probability of HIV infection in donated allogeneic blood was derived from the most recent survey of donors who gave blood between 1991 and 1993 (Schreiber et al, 1996) . The figure ascertained of 1 in 493 000 was in the range of values estimated from demographic and laboratory data on more than 4.1 million blood donations made in 1992 and 1993 in the US; a risk of one case of HIV transmission for every 450 000-660 000 donations of screened blood (Lackritz et al, 1996) Cost of transfusions Because the real cost of blood transfusions varies from centre to centre, we decided it would be unreliable to determine this amount with data from a single institution. The estimated average direct cost of one allogeneic blood unit ranges from $149.80 (Etchason et al, 1995) to $422 (Mohandas and Aledort, 1995) . To bias our results in favour of rHuEPO, we considered the baseline unit cost to be $422. A breakdown of this estimate includes blood collection, infectious disease testing, blood processing, inventory management and compatibility testing. The cost of treating transfusion-related complications was derived from a recent estimate (Wong et al, 1995) . According to British Journal of Cancer (1998) 78(6), [781] [782] [783] [784] [785] [786] [787] (Tretiak et al, 1996) This amount is also higher than the mean cost of transfusion in Italy, which was estimated to be approximately $250 (F Mercuriali, personal comunication) .
Quality of life adjustment
Quality of life (QOL) adjustment included explicit considerations of the degree to which disease states diminish the well-being of patients. At baseline, we used the overall QOL score, provided on a visual analogue scale by the patients in the community oncology setting, which measures separately the effect of the amelioration of anaemia and that of tumour response (Glaspy, 1997) . The QOL of cancer patients was low at baseline -46.8 on a scale from 0 to 100 -and the net improvement in QOL due to amelioration of anaemia was 14.4. The same QOL improvement was used also for patients heavily transfused so as to reach the same haemoglobin level of rHuEPO responding patients. In cisplatin-treated patients (Abels et al, 1992) , the QOL score rose from 50 to 74 in rHuEPO responders. Adjustments for the QOL related to post-transfusional hepatitis and HIV infection were derived from the literature (Table  3) . Chronic disease states were assigned a quality adjustment factor from 0.50 to 0.94, meaning that a year of life with the symptoms of hepatitis or HIV complications was considered to be worth only a corresponding fraction of a year of life without them.
RESULTS
In the baseline analysis, saving RBC transfusions by rHuEPO administration increases quality-adjusted life expectancy by 8.4 days. However, the average cost of adding rHuEPO to transfusions ($4568) was $4362 greater than that of RBC transfusions alone ($206), corresponding to an incremental cost-effectiveness of $189 652 per quality-adjusted life-year (QALY).
In sensitivity analysis, transfusion therapy alone remained the most cost-effective strategy, even with a risk of blood-borne infections up to double the mean values reported in the literature. For these latter values, rHuEPO still adds more than $100 000 to the cost per QALY gained. We next analysed changes in the efficacy of rHuEPO assuming a normal life expectancy for cancer patients. Even with this highly favourable assumption, the marginal costeffectiveness of rHuEPO was high: rHuEPO would mean more than an additional $100 000 per quality-adjusted life year in both a 65-and a 25-year-old patient. The results were insensitive to other uncertain variables. A 30% increase in the QOL of responding patients did not alter the qualitative results of our analysis; rHuEPO would cost an additional $145 400 per quality-adjusted life year.
The model variables that significantly modified the results were the price and the efficacy of rHuEPO. The incremental cost-effectiveness dropped below $100 000 per QALY gained, only at a drug cost of $2250 per 4 months of treatment, i.e. when the price was reduced to 50% of its basal value. Increasing the efficacy of 
to be transfused despite treatment (Case et al, 1993; Cascinu et al, 1994; Henry et al, 1994; Wurning et al, 1996; Glaspy et al, 1997) . Our analysis of treatment with rHuEPO as compared with blood transfusion alone shows that, at the current response rate, every QALY gained costs approximately $190 000. Compared with other forms of clinical therapy, rHuEPO in the anaemia of chemotherapy is a highly expensive tool. To achieve one QALY with rHuEPO for the anaemia of end-stage renal disease, for instance, costs approximately $20 000 (Nicholls, 1992) , i.e. more than nine times cheaper. Moreover, this figure is well above the estimated cost per QALY for a number of other health care therapies (Maynard, 1991) . This is true even when a particularly high cost for a RBC transfusion unit is adopted in the baseline model, and when values highly favourable to rHuEPO are set in the sensitivity analysis, such as the incidence of transfusion-related diseases, improvement in the patient's QOL after improvement of anaemia and life expectancy for cancer patients. As both the type of cancer and the type of chemotherapy influence the effectiveness of rHuEPO, our analysis included an alternative scenario which considered patients treated with cisplatin-containing chemotherapy. At the current efficacy of rHuEPO, the proportion of patients under the drug who continue to be transfused is so high that the costeffectiveness ratio was greater than $100 000 per QALY.
The above-reported results are in agreement with a previously published cost analysis of rHuEPO in cancer chemotherapy. In a cost comparison of rHuEPO vs leucocyte-depleted RBC transfusion therapy, with a response rate of 64% with rHuEPO, full cost of the drug and 8 months of therapy, RBC transfusion resulted in a saving of $8490 per patient (Sheffield et al, 1997) . In a cost-effectiveness analysis that considered a longer duration for therapy and efficacy data from clinical trials (Barosi and Liberato, 1995) , the baseline cost-effectiveness ratio was more than $100 000 per QALY.
An alternative way to reduce the need for blood transfusions in cancer patients under chemotherapy might be to use rHuEPO in primary prophylaxis, i.e. in patients with normal or only slightly reduced haemoglobin values before any chemotherapy is started. A recent analysis of this modality (Del Mastro et al, 1997) documented that throughout six cycles of chemotherapy non-rHuEPOtreated patients developed anaemia, but only 2 out of 31 of them needed RBC transfusions. Given the higher cost component of RBC transfusions avoided, as shown by the present analysis, this strategy would be more expensive and less cost-effective than secondary prophylaxis.
At baseline, the results of this study portray the use of transfusions and of rHuEPO as derived from a community-based survey. However, one could comment that, to obtain a more reasonable comparison, the costs of rHuEPO need to be compared with the costs which would be incurred if sufficient blood transfusion was used to mimic the steady haemoglobin level achieved with rHuEPO in patients who respond to the therapy. This calculation was made in a scenario analysis. Using the increased level of blood transfusion estimated to give a similar outcome to rHuEPO therapy, the costs of managing these patients is still more than $100 000 per QALY.
Economic analysis of medical technology is a useful tool for focusing on ways to utilize the technology more rationally. Our analysis pointed out that the greatest challenge to cost-effective use of rHuEPO is to improve the drug's power to reduce the number of units of blood transfused. This points at improving response predictability. An inadequate serum erythropoietin level British Journal of Cancer (1998) 78(6), 781-787 before therapy (Cazzola et al, 1995) and a serum erythropoietin level lower than 100 mU ml-' associated with a haemoglobin concentration increased by at least 0.5 g dl-' after 2 weeks of therapy (Ludwig et al, 1994) have both been reported to predict responsiveness. A narrower target for rHuEPO therapy can be clinically implemented and studied as an effective blood-sparing alternative. A prospective trial on the use of rHuEPO limited to patients who have the characteristics that predict the response to the drug is warranted. In that trial, besides health outcomes, the economic component should be measured.
